These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17092516)

  • 1. Statistical analysis of longitudinal psychiatric data with dropouts.
    Mazumdar S; Tang G; Houck PR; Dew MA; Begley AE; Scott J; Mulsant BH; Reynolds CF
    J Psychiatr Res; 2007 Dec; 41(12):1032-41. PubMed ID: 17092516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A structured framework for assessing sensitivity to missing data assumptions in longitudinal clinical trials.
    Mallinckrodt CH; Lin Q; Molenberghs M
    Pharm Stat; 2013; 12(1):1-6. PubMed ID: 23193075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of data analysis strategies for intent-to-treat analysis in pre-test-post-test designs with substantial dropout rates.
    Salim A; Mackinnon A; Christensen H; Griffiths K
    Psychiatry Res; 2008 Sep; 160(3):335-45. PubMed ID: 18718673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A local sensitivity analysis approach to longitudinal non-Gaussian data with non-ignorable dropout.
    Xie H
    Stat Med; 2008 Jul; 27(16):3155-77. PubMed ID: 17948917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of OSWALD for analyzing longitudinal data with informative dropout.
    Begley AE; Tang G; Mazumdar S; Houck PR; Scott J; Mulsant BH; Reynolds CF
    Comput Methods Programs Biomed; 2007 Feb; 85(2):109-14. PubMed ID: 17141356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dropouts in longitudinal studies: definitions and models.
    Lindsey JK
    J Biopharm Stat; 2000 Nov; 10(4):503-25. PubMed ID: 11104390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dropouts and missing data in psychiatric clinical trials.
    Potkin SG; Siu CO
    Am J Psychiatry; 2009 Nov; 166(11):1295; author reply 1295-6. PubMed ID: 19884237
    [No Abstract]   [Full Text] [Related]  

  • 8. Multiple imputation compared with some informative dropout procedures in the estimation and comparison of rates of change in longitudinal clinical trials with dropouts.
    Ali MW; Siddiqui O
    J Biopharm Stat; 2000 May; 10(2):165-81. PubMed ID: 10803723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-random dropout and the relative efficacy of escitalopram and nortriptyline in treating major depressive disorder.
    Power RA; Muthén B; Henigsberg N; Mors O; Placentino A; Mendlewicz J; Maier W; McGuffin P; Lewis CM; Uher R
    J Psychiatr Res; 2012 Oct; 46(10):1333-8. PubMed ID: 22770672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A joint model for nonlinear longitudinal data with informative dropout.
    Hu C; Sale ME
    J Pharmacokinet Pharmacodyn; 2003 Feb; 30(1):83-103. PubMed ID: 12800808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A latent variable approach in simultaneous modeling of longitudinal and dropout data in schizophrenia trials.
    Goyal N; Gomeni R
    Eur Neuropsychopharmacol; 2013 Nov; 23(11):1570-6. PubMed ID: 23602612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of placebo arms on outcomes in antidepressant trials: systematic review and meta-regression analysis.
    Salanti G; Chaimani A; Furukawa TA; Higgins JPT; Ogawa Y; Cipriani A; Egger M
    Int J Epidemiol; 2018 Oct; 47(5):1454-1464. PubMed ID: 29878123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling placebo response in depression trials using a longitudinal model with informative dropout.
    Gomeni R; Lavergne A; Merlo-Pich E
    Eur J Pharm Sci; 2009 Jan; 36(1):4-10. PubMed ID: 19041717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials.
    Pilla Reddy V; Kozielska M; Johnson M; Suleiman AA; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
    Clin Pharmacokinet; 2012 Apr; 51(4):261-75. PubMed ID: 22420580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A transition model for ordinal response data with random dropout: an application to the fluvoxamine data.
    Ghahroodi ZR; Ganjali M; Berridge D
    J Biopharm Stat; 2009 Jul; 19(4):658-71. PubMed ID: 20183432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelling variable dropout in randomised controlled trials with longitudinal outcomes: application to the MAGNETIC study.
    Kolamunnage-Dona R; Powell C; Williamson PR
    Trials; 2016 Apr; 17(1):222. PubMed ID: 27125779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian informative dropout model for longitudinal binary data with random effects using conditional and joint modeling approaches.
    Chan JS
    Biom J; 2016 May; 58(3):549-69. PubMed ID: 26467236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intent-to-treat analysis for longitudinal clinical trials: coping with the challenge of missing values.
    Mazumdar S; Liu KS; Houck PR; Reynolds CF
    J Psychiatr Res; 1999; 33(2):87-95. PubMed ID: 10221740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haplotype-based pharmacogenetic analysis for longitudinal quantitative traits in the presence of dropout.
    Tzeng JY; Lu W; Farmen MW; Liu Y; Sullivan PF
    J Biopharm Stat; 2010 Mar; 20(2):334-50. PubMed ID: 20309762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accounting for dropout bias using mixed-effects models.
    Mallinckrodt CH; Clark WS; David SR
    J Biopharm Stat; 2001; 11(1-2):9-21. PubMed ID: 11459446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.